SCHEMBL18340892

SCHEMBL18340892

COC(=O)CCC(=O)c1cccc(Br)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.50
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 2/20 0.48
TP53 P04637 1/20 0.48
HSD17B10 Q99714 1/20 0.48
MAPK1 P28482 1/20 0.48
PARP1 P09874 1/20 0.47
HPGD P15428 2/20 0.47
LMNA P02545 1/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
CYP1A2 P05177 2/20 0.47
ATM Q13315 2/20 0.47
RXFP1 Q9HBX9 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
CTNNB1 P35222 1/20 0.46
WNT3A P56704 1/20 0.46
GLA P06280 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6138872 0.91 LMNA (0.48) L3MBTL1ALDH1A1KDM4EMAPK1PARP1
SCHEMBL13918097 0.87 L3MBTL1 (0.53) L3MBTL1ALDH1A1KDM4EMAPK1PARP1
SCHEMBL15058686 0.86 RXFP1 (0.51) L3MBTL1ALDH1A1KDM4EMAPK1PARP1
SCHEMBL30666326 0.86 RXFP1 (0.51) L3MBTL1ALDH1A1KDM4EMAPK1PARP1
SCHEMBL22868041 0.82 CTNNB1 (0.66) ALDH1A1KDM4EHSD17B10PARP1HPGD
SCHEMBL11632592 0.82 CTNNB1 (0.52) ALDH1A1KDM4EHSD17B10PARP1LMNA
SCHEMBL1814265 0.81 SMN1; SMN2 (0.56) L3MBTL1ALDH1A1KDM4ETP53MAPK1
SCHEMBL3456365 0.81 L3MBTL1 (0.57) L3MBTL1ALDH1A1KDM4ETP53MAPK1
SCHEMBL3588375 0.81 CTNNB1 (0.60) ALDH1A1HSD17B10PARP1HPGDMEN1
SCHEMBL315926 0.81 CTNNB1 (0.54) ALDH1A1KDM4EHSD17B10PARP1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3313828-B1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-07-12 EP disclosed
CN-110016034-A Imidazoles [1,2-a] [1,3,5] triazine formic ether compounds and the preparation method and application thereof 浙江工业大学 2019-07-16 CN disclosed
US-10227331-B2 Metallo-β-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2019-03-12 US disclosed
US-20180179190-A1 METALLO-BETA-LACTAMASE INHIBITORS Marck Sharp & Dohme Corp. (US) 2018-06-28 US disclosed
EP-3313828-A1 METALLO-BETA-LACTAMASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2018-05-02 EP disclosed
WO-2016206101-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-12-29 WO disclosed
WO-2016210234-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10227331-B2 Metallo-β-lactamase inhibitors ALPI, GAA, ZFX L3MBTL1 1272/4885ALDH1A1 310/4885KDM4E 1601/4885
US-20180179190-A1 METALLO-BETA-LACTAMASE INHIBITORS ALPI, GAA, ZFX L3MBTL1 1238/4885ALDH1A1 319/4885KDM4E 1651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.